Metabolism of the new nonbenzodiazepine anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9 fractions, and in rats, dogs and humans
- 53 Downloads
The in vitro and in vivo metabolism of the nonbenzodiazepine anxiolytic agent, RWJ-51204 was investigated after incubation with mice, rat, dog, monkey, and human hepatic S9 fractions in the presence of NADPH-generating system, and a single oral dose administration to rats (100 mg/kg), dogs (5 mg/kg), and humans (2.5 mg/subject). Plasma and red blood cells (2 h, rat) and urine samples (0–24 h, rat, dog and human) were obtained postdose. Unchanged RWJ-51204 (39–93% of the sample in vitro; ≤5% of the sample in vivo) plus 14 metabolites were profiled, quantified and tentatively identified on the basis of API-MS and MS/MS data, and by comparison of synthetic samples.
The in vitro and in vivo metabolic pathways for RWJ-51204 are proposed, and the metabolite formations are via the following five pathways: 1. phenyl oxidation, 2. pyrido-oxidation, 3. N-deethoxymethylation, 4. dehydration, and 5. glucuronidation. Pathway 1 formed 4-hydroxy-2-fluoro-phenyl-RWJ-51204 (Ml, 7–24% in vitro; 5–60% in vivo) in major amounts, OH-benzimidazole-RWJ-51204 (M2, 5–8% in vitro and in vivo) and diOH-phenyl-RWJ-51204 (≤5–16% in vitro and in vivo); in conjunction with pathway 5 produced Ml glucuronide (60% in rat & dog; 17% in human), M2 glucuronide (16% in human). Pathways 2–4 formed minor/trace oxidized, and dehydrated metabolites. RWJ-51204 is extensively metabolized in vitro (except dog) and in vivo in rats, dogs and humans.
KeywordsRWJ-51204 anxiolytic agent in vitro & in vivo metabolism animals human ms & ms/ms metabolite identification
Unable to display preview. Download preview PDF.
- 1.Maryanoff, B.E., Ho, W., McComsey, D.F., Reitz, A.B., Grous, P.P, Nortey, S.O., Shank, R.P., Dubinsky, B., Taylor, Jr., R.J, Gardocki, J.F., (1995): Potential anxiolytic agents, pyrido[l,2-a]benzimidazole: anew structural class of ligands for the benzodiazepine binding site on GABA-A receptors, J. Med. Chem., 38,16–20.CrossRefPubMedGoogle Scholar
- 3.Reitz, A.B., Jordan, A.D., Sanfilippo, P.J., and Vavouyios-Smith, A., ( 1998): US Patent, 5,817,668,6.Google Scholar
- 6.Jordan, A.D., Vaidya, A.H., Rosenthal, D.I., Dubinsky, B., Kordik, C.P., Sanfilippo, P.J., Wu, W.N., and Reitz, A.B., (2002): Potential anxiolytic agents, part 4: novel orally-active N5-substituted pyrido[l,2-a]benzimidazoles with high GABA-A receptor affinity, Bioorg. Med. Chem. Lett.,12,2381–2386.CrossRefPubMedGoogle Scholar
- 7.Dubinsky, B., Vaidya, A.H., Rosenthal, D.I., Hochman, C., Crooke, J.J., Deluca, S., Devine, A., Cheo-Isaacs, C.T., Carter, A.R., Jordan, A.D., Reitz, A.B. and Shank, R.P., (2002): 5-Ethoxymethyl-7-fluoro-3-oxo-l,2,3,5-tetrahydrobenzo[4,5]imidazo [l,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic, J. Pharmacol. Exp. Ther., 303,777–790.CrossRefPubMedGoogle Scholar
- 8.Wu, W.N., McKown, L.A., Reitz, A.B., andTakacs, A.R., (1998): In vitro metabolism of the anxiolytic agent, RWJ-51204, in mouse, rat, dog, monkey and human hepatic S9. The AAPS Annual Meeting and Exposition, Abstract no. 1167, Pharm. Sei., 1, PS36.Google Scholar
- 9.Wu, W.N., and McKown, L.A., (1999): In vivo metabolism of anxiolytic agent, RWJ-51204, in the rat and dog, The 9th N. Amer. ISSX/ACS-DCT Meeting, Abstract no. 34, ISSX Proceedings, 15,174.Google Scholar
- 10.Wu, W.N., McKown, L.A., and Reitz, A.B., (2002): Metabolism of the anxiolytic agent, RWJ-51204, in human (2.5 mg/subject single oral dose), catalyzed by CYP3A4 isoform, The 11th N. Amer. ISSX Meeting, Abstract no. 163, Drug Metab. Rev., 34,82.Google Scholar